Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy

Prostate Cancer Foundation| Tue Jun 06 16:13:02 EDT 2017
Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy

A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that men who develop metastatic hormone therapy-resistant prostate cancer (mHRPC) have similar outcomes if prescribed either abiraterone or enzalutamide.  Abiraterone and enzalutamide are two hormonal therapies that can be used as first line treatment for men with mHRPC, but have never been directly compared in clinical trials.  There are no tests to help patients choose betwee....

Read at Source
Related News